Regeneron Pharmaceuticals Inc (REGN.OQ)
19 Sep 2018
(This version of the Sept. 14th story has been refiled to add dropped words in fifth paragraph)
PARIS, Sept 14 Sanofi will continue to implement cost savings after having reached a 1.5 billion euros ($1.75 billion) cost reduction target a year ahead of expectations, and added that several of its key drugs were selling well.
FRANKFURT Bayer is considering job cuts and outsourcing as part of a wide-ranging review of drug research and development that will last until at least November, a person familiar with the company told Reuters.
Aug 17 Regeneron said on Friday it had won U.S. Food and Drug Administration approval for less-frequent applications of its Eylea anti-blindness treatment, which may come under pressure from a rival product made by Novatis
Regeneron Pharmaceuticals Inc said on Monday it will invest $100 million in cancer drug developer bluebird bio Inc, and the companies will jointly develop new cell therapies for cancer.
Regeneron Pharmaceuticals Inc reported a better-than-expected quarterly profit on Thursday, helped by higher sales of its newer medicines and outlined a growth strategy for its flagship drug Eylea, which is facing heightened competition.
Aug 2 Drugmaker Regeneron Pharmaceuticals Inc reported a better-than-expected quarterly profit, helped by higher sales of eczema drug Dupixent.
PARIS Sanofi believes it can make a comeback and re-establish a leading position in the competitive cancer drug market on the back of its immunotherapy drugs and efforts in new areas such as molecular oncology.
PARIS, June 13 Sanofi believes it can make a comeback and re-establish a leading position in the competitive cancer drug market on the back of its immunotherapy drugs and efforts in new areas such as molecular oncology.
Regeneron Pharmaceuticals Inc disappointed Wall Street with lower-than-expected sales of its newer treatments, eczema medicine Dupixent and heart drug Praluent, exacerbating concerns over the company's future sales growth as its best-selling eye drug Eylea faces more competition.
|Novartis AG (NOVN.S)||CHF81.78||+0.04|
|Pfizer Inc. (PFE.N)||$43.26||-0.25|
|Bayer AG (BAYGn.DE)||€75.06||+1.03|
|Bayer AG (BAYE.F)||--||--|
|Sanofi SA (SASY.PA)||€74.58||-0.54|
|Merck & Co., Inc. (MRK.N)||$69.98||-0.44|
|Amgen, Inc. (AMGN.OQ)||$203.20||--|
|Roche Holding Ltd. (ROG.S)||CHF235.85||-0.65|
|Roche Holding Ltd. (RO.S)||CHF237.80||-0.80|
|Eli Lilly And Co (LLY.N)||$105.74||-1.14|